Format

Send to

Choose Destination
Haematologica. 2016 Dec;101(12):1581-1591. Epub 2016 Aug 11.

Non-Hodgkin lymphoma and pre-existing conditions: spectrum, clinical characteristics and outcome in 213 children and adolescents.

Author information

1
Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Austria andishe.attarbaschi@stanna.at.
2
Pediatric Hematology and Oncology, University of Padova, Italy.
3
Depar tment of Pediatrics, Division of Hematology and Oncology, Hospital for Sick, Children, Toronto, Canada.
4
Pediatric Hematology and Oncology, Schneider Children's, Medical Center of Israel, Petah-Tivka, Israel and Sackler Faculty of Medicine, Tel Aviv, University, Israel.
5
Northern Institute for Cancer Research, Newcastle University, UK.
6
Department of Pediatric Oncology, Institute Gustave-Roussy, Villejuif, France.
7
Department of Pediatric Oncology and Hematology, University Children's Hospital, Banska Bystrica, Slovakia.
8
Pediatric Hematology and Oncology, University of Munster, Germany.
9
Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong.
10
Pediatric Hematology and Oncology, Semmelweis University, Budapest, Hungary.
11
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Belarus.
12
Division of Pediatrics, Hematology and Oncology, University Medical Center Ljubljana, Slovenia.
13
Pediatric Hematology and Oncology, Charles University and University Hospital Motol, Prague, Czech Republic.
14
Pediatric Hematology and Oncology, University Hospital, Brno, Czech Republic.
15
Pediatric Hematology and Oncology, University Children's Hospital, School of Medicine University of Belgrade, Serbia.
16
Pediatric Hematology and Oncology, Erasmus MC - Sophia Children's Hospital, Rotterdam, the Netherlands.
17
Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Austria.
18
Pediatric Hematology and Oncology, University Hospital, Zurich, Switzerland.
19
Pediatric Hematology and Oncology, Federal Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
20
Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
21
Pediatric Hematology and Oncology, University Hospitals Leuven, Belgium.
22
Pediatric Hematology and Oncology, Cambridge University Hospitals Foundation Trust, Addenbrooke's Hospital, Cambridge, UK.
23
Pediatric Hematology and Oncology, Justus Liebig University, Giessen, Germany.
24
Bone Marrow Transplantation and Pediatric Hematology and Oncology, Wroclaw Medical University, Poland.

Abstract

Children and adolescents with pre-existing conditions such as DNA repair defects or other primary immunodeficiencies have an increased risk of non-Hodgkin lymphoma. However, large-scale data on patients with non-Hodgkin lymphoma and their entire spectrum of pre-existing conditions are scarce. A retrospective multinational study was conducted by means of questionnaires sent out to the national study groups or centers, by the two largest consortia in childhood non-Hodgkin lymphoma, the European Intergroup for Childhood non-Hodgkin Lymphoma, and the international Berlin-Frankfurt-Münster Study Group. The study identified 213 patients with non-Hodgkin lymphoma and a pre-existing condition. Four subcategories were established: a) cancer predisposition syndromes (n=124, 58%); b) primary immunodeficiencies not further specified (n=27, 13%); c) genetic diseases with no increased cancer risk (n=40, 19%); and d) non-classifiable conditions (n=22, 10%). Seventy-nine of 124 (64%) cancer predispositions were reported in groups with more than 20 patients: ataxia telangiectasia (n=32), Nijmegen breakage syndrome (n=26), constitutional mismatch repair deficiency (n=21). For the 151 patients with a known cancer risk, 5-year event-free survival and overall survival rates were 40%±4% and 51%±4%, respectively. Five-year cumulative incidences of progression/relapse and treatment-related death as a first event were 22%±4% and 24%±4%, respectively. Ten-year incidence of second malignancy was 24%±5% and 7-year overall survival of the 21 patients with a second malignancy was 41%±11%. Patients with non-Hodgkin lymphoma and pre-existing conditions have an inferior survival rate with a large proportion of therapy-related deaths compared to patients with non-Hodgkin lymphoma and no pre-existing conditions. They may require special vigilance when receiving standard or modified/reduced-intensity chemotherapy or when undergoing allogeneic stem cell transplantation.

PMID:
27515251
PMCID:
PMC5479624
DOI:
10.3324/haematol.2016.147116
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center